Evidence map›Paper›PMID 41012543›Full record

ArticlePharmaceutics2025

Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer.

Elena Peira, Simona Sapino, Daniela Chirio, Fabio Bucciol, Flavia Turku, Emanuela Calcio Gaudino, Giancarlo Cravotto, Chiara Riganti, Marina Gallarate

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elena PeiraDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-8017-4956
Simona SapinoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-5335-8442
Daniela ChirioDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-4615-5812
Fabio BucciolDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0003-0548-9127
Flavia TurkuDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0009-0005-0125-9940
Emanuela Calcio GaudinoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-9602-0310
Giancarlo CravottoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-7574-7350
Chiara RigantiDepartment of Oncology, University of Torino, Via Santena 5/bis, 10126 Turin, Italy.ORCID 0000-0001-9787-4836
Marina GallarateDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-8185-1672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hydroxytyrosolcarboxylic acid estersnanostructured lipid carrierssolid lipid nanoparticlestriple-negative breast cancer

Identifiers

PMID41012543
PMCPMC12473461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.